Works Cited

1. Centers for Disease Control and Prevention. Vision Health Initiative (VHI). Available at https://www.cdc.gov/visionhealth. Last accessed October 1, 2023.

2. Channa R, Zafar SN, Canner JK, et al. Epidemiology of eye-related emergency department visits. JAMA Ophthalmol. 2016;134(3):312-319.

3. ٣. Rein DB, Wittenborn JS, Zhang P, et al. The Economic Burden of Vision Loss and Blindness in the United States. Ophthal. 2022;129(4):369-378.

4. Owens PL, Mutter R. Emergency department visits related to eye injuries. Statistical Brief #112. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

5. American Academy of Ophthalmology. Eye Health Statistics. Available at https://www.aao.org/newsroom/eye-health-statistics. Last accessed October 1, 2023.

6. Saydah SH, Gerzoff RB, Saadine JB, et al. Eye care among U.S. adults at high risk for vision loss in the United States in 2002 and 2017. JAMA Ophthalmol. 2020;138:479-489.

7. Flaxman AD, Wittenborn JS, Robalik T, et al. Prevalence of visual acuity loss or blindness in the U.S. JAMA Ophthalmology.2021;139(7):171-123.

8. American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation PPP 2020. Available at https://www.aao.org/education/preferred-practice-pattern/comprehensive-adult-medical-eye-evaluation-ppp. Last accessed October 1, 2023.

9. Anzeljc S, Ziemnik L, Koscher S, et al. Preschool vision screening collaborative: successful uptake of guidelines in primary care. Ped Qual Saf. 2019;4(6):e241.

10. American Academy of Ophthalmology. Conjunctivitis PPP 2018. Available at https://www.aao.org/education/preferred-practice-pattern/conjunctivitis-ppp-2018. Last accessed October 1, 2023.

11. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines. Available at https://www.aaojournal.org/content/preferred-practice-pattern. Last accessed October 1, 2023.

12. Sales, Patel, Patel. Eye Tray. Eye tray. Crit Dec Emerg Med. 2019;33(12):3-13.

13. 13.Newman NJ. The Optic Neuritis Treatment Trial. Available at https://www.aaojournal.org/article/S0161-6420(19)32364-4/pdf. Last accessed October 1, 2023.

14. Wittenborn JS, Rein DB. The Future of Vision: Forecasting the Prevalence and Cost of Vision Problems. Available at https://preventblindness.org/wp-content/uploads/2020/04/Future_of_Vision_final_0.pdf. Last accessed October 1, 2023.

15. American Optometric Association. Blepharitis. Available at https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/blepharitis. Last accessed October 1, 2023.

16. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275-1279.

17. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs. 2007;67(1):75-93.

18. 18.Ahmad R, Mehta H. The ocular adverse effects of oral drugs. Aust Prescr. 2021;44(4):129-136.

19. 19. American Academy of Ophthalmology. Dry Eye Syndrome PPP 2018. Available at https://www.aao.org/education/preferred-practice-pattern/dry-eye-syndrome-ppp-2018. Last accessed October 1, 2023.

20. Wilkinson JT, Fraunfelder FW. Use of herbal medicines and nutritional supplements in ocular disorders: an evidence-based review. Drugs. 2011;71(18):2421-2434.

21. Gray H. Gray's Anatomy: Descriptive and Surgical. New York, NY: Cosimo Classics; 2011.

22. Mafee MF, Karimi A, Shah JD, Rapoport M, Ansari SA. Anatomy and pathology of the eye: role of MR imaging and CT. Magn Reson Imaging Clin North Am. 2006;14(2):249-270.

23. McIlwain JT. An Introduction to the Biology of Vision. Cambridge: Cambridge University Press; 1996.

24. Moses K, Banks JC, Nava PB, Petersen D. Atlas of Clinical Gross Anatomy. 2nd ed. Philadelphia, PA: Saunders; 2012.

25. American Optometric Association. Comprehensive Adult Eye and Vision Examination. Available at https://aoa.uberflip.com/i/578152-aoa-clinical-practice-guidelines-adult-eye-exam. Last accessed October 1, 2023.

26. U.S. Preventive Services Task Force. Vision in Children Ages 6 Months to 5 Years: Screening. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vision-in-children-ages-6-months-to-5-years-screening. Last accessed October 1, 2023.

27. American Optometric Association. Pediatric Eye and Vision Examination. Available at https://aoa.uberflip.com/i/807465-cpg-pediatric-eye-and-vision-examination. Last accessed October 1, 2023.

28. U.S. Preventive Services Task Force. Impaired Visual Acuity in Older Adults: Screening. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/impaired-visual-acuity-screening-older-adults. Last accessed October 1, 2023.

29. American Academy of Ophthalmology. Cataract in the Adult Eye PPP 2021. Available at https://www.aao.org/education/preferred-practice-pattern/cataract-in-adult-eye-ppp-2021-in-press. Last accessed October 1, 2023.

30. Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111(10):1930-1932.

31. Bader RS. Basal Cell Carcinoma. Available at https://emedicine.medscape.com/article/276624-overview. Last accessed October 1, 2023.

32. Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531-550.

33. Kemper AR, Clark SJ. Preschool vision screening by family physicians. J Pediatr Ophthalmol Strabismus. 2007;44(1):24-27.

34. American Academy of Ophthalmology. Primary Angle-Closure Disease PPP 2020. Available at https://www.aao.org/education/preferred-practice-pattern/primary-angle-closure-disease-ppp. Last accessed October 1, 2023.

35. Wickstrom GC, Kelley DK, Keyserling TC, et al. Confidence of academic general internists and family physicians to teach ambulatory procedures. J Gen Intern Med. 2000;15(6):353-360.

36. Bonds DE, Mychaleckyj JC, Watkins R, Palla S, Extrom P. Ambulatory care skills: do residents feel prepared? Med Educ Online. 2002;7.

37. American Academy of Ophthalmology. Joint Policy Statement: Vision Screening for Infants and Children—2022. Available at https://www.aao.org/education/clinical-statement/vision-screening-infants-children-2022. Last accessed October 1, 2023.

38. Goldzweig CL, Rowe S, Wenger NS, MacLean CH, Shekelle PG. Preventing and managing visual disability in primary care: clinical applications. JAMA. 2004;291(12):1497-1502.

39. McGee S. Evidence-Based Physical Diagnosis. 4th ed. Philadelphia, PA: Saunders; 2017.

40. American Academy of Ophthalmology. Referral of Persons with Possible Eye Diseases or Injury - 2014. Available at https://www.aao.org/education/clinical-statement/guidelines-appropriate-referral-of-persons-with-po. Last accessed October 1, 2023.

41. American Academy of Pediatrics, the American Association for Pediatric Ophthalmology and Strabismus, and the American Association of Certified Orthoptists. Visual system assessment in infants, children, and young adults by pediatricians: policy statement, 2016. Pediatrics. 2016;137(1):e20153596.

42. Friedman LS, Kaufman LM. Guidelines for pediatrician referrals to the ophthalmologist. Pediatr Clin North Am. 2003;50(1):41-53.

43. Kempen JH, Mitchell P, Lee KE, et al. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol. 2004;122(4):495-505.

44. Wen G, Tarczy-Hornoch K, McKean-Cowdin R, et al. Prevalence of myopia, hyperopia, and astigmatism in non-Hispanic white and Asian children: Multi-ethnic Pediatric Eye Disease Study. Ophthalmology. 2013;120(10):2109-2116.

45. Borchert MS, Varma R, Cotter SA, et al. Risk factors for hyperopia and myopia in preschool children the Multi-ethnic Pediatric Eye Disease and Baltimore Pediatric Eye Disease studies. Ophthalmology. 2011;118(10):1966-1973.

46. Ying GS, Maguire MG, Cyert LA, et al. Prevalence of vision disorders by racial and ethnic group among children participating in Head Start. Ophthalmology. 2014;121(3):630-636.

47. Fozailoff A, Traczy-Hornoch K, Cotter S, et al. Prevalence of astigmatism in 6- to 72-month-old African American and Hispanic children: the Multi-ethnic Pediatric Eye Disease Study. Ophthalmology. 2011;118(2):284-293.

48. McKean-Cowdin R, Cotter SA, Tarczy-Hornoch K, et al. Prevalence of amblyopia or strabismus in Asian and non-Hispanic white preschool children: Multi-ethnic Pediatric Eye Disease Study. Ophthalmology. 2013;120(10):2117-2124.

49. Tarczy-Hornoch K, Varma R, Cotter SA, et al. Risk factors for decreased visual acuity in preschool children: the Multi-ethnic Pediatric Eye Disease and Baltimore Pediatric Eye Disease studies. Ophthalmology. 2011;118(11):2262-2273.

50. Shah SM, Khanna CL. Ophthalmic emergencies for the clinician. Mayo Clin Proc. 2020;95(5):1050-1058.

51. Bureau of Labor Statistics. Workers suffered 18,510 eye-related injuries and illnesses in 2020. Available at https://www.bls.gov/opub/ted/2023/workers-suffered-18510-eye-related-injuries-and-illnesses-in-2020.htm. Last accessed October 1, 2023.

52. Azari AA, Arabi A. Conjunctivitis: a systematic review. J Ophthalmic Vis Res. 2020;15(3):372-395.

53. Taukikewa M, Stacey AW. A review of hypertensive retinopathy and chorioretinopathy. Clin Optom (Auckl). 2020;12:67-73.

54. U.S. Food and Drug Administration. FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions. Last accessed October 1, 2023.

55. Centers for Disease Control and Prevention. Conjunctivitis (Pink Eye). Available at https://www.cdc.gov/conjunctivitis/clinical.html. Last accessed October 1, 2023.

56. Porter RS, Kaplan JL, Homeier BP (eds). The Merck Manual of Patient Symptoms. Whitehouse Station, NJ: Merck Research Laboratories; 2008.

57. Gilliland GD. Dacryocystitis. Available at https://emedicine.medscape.com/article/1210688-overview?form=fpf. Last accessed October 1, 2023.

58. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27(1):22-27.

59. Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M (eds). The Merck Manual. 20th ed. Whitehouse Station, NJ: Merck Research Laboratories, 2018.

60. Collier SA, Gronostaj MP, MacGurn AK, et al. Estimated burden of keratitis—United States, 2010. MMWR. 2014;63(45):1027-1030.

61. Centers for Disease Control and Prevention. Healthy Contact Lens Wear and Care. Available at https://www.cdc.gov/contactlenses/fast-facts.html. Last accessed October 1, 2023.

62. American Academy of Ophthalmology. Red Eye. Available at https://www.aao.org/eye-health/symptoms/red-eye-3. Last accessed October 1, 2023.

63. Mills DM, Bodman MG, Meyer DR, Morton AD 3rd. The microbiologic spectrum of dacryocystitis: a national study of acute versus chronic infection. Ophthal Plast Reconstr Surg. 2007;23(4):302-306.

64. Kubo M, Sakuraba T, Arai Y, Nakazawa M. Dacryocystorhinostomy for dacryocystitis caused by methicillin-resistant Staphylococcus aureus: report of four cases. Jpn J Ophthalmol. 2002;46(2):177-182.

65. Kotlus BS, Rodgers IR, Udell IJ. Dacryocystitis caused by community-onset methicillin-resistant Staphylococcus aureus. Ophthal Plast Reconstr Surg. 2005;21(5):371-375.

66. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2011;118(10):1916-1926.

67. Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-Up Study Research Group. Association between long-lasting intravitreous flucinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317(19):1993-2005.

68. Jackson TL, Paraskevopoulos T, Georgalas I. Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014;59(6):627-635.

69. Pijl BJ, Theelen T, Tilanus MA, Rentenaar R, Crama N. Acute endophthalmitis after cataract surgery: 250 consecutive cases treated at a tertiary referral center in the Netherlands. Am J Ophthalmol. 2010;149(3):482-487.

70. Essex RW, Yi Q, Charles PG, Allen PJ. Post-traumatic endophthalmitis. Ophthalmology. 2004;111(11):2015-2022.

71. Callegan MC, Engelbert M, Parke DW 2nd, Jett BD, Gilmore MS. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002;15(1):111-124.

72. Gower EW, Lindsley K, Tulenko SE, Nanji AA, Leyngold I, McDonnell PJ. Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev. 2017;2:CD006364.

73. Kim CH, Chen ME, Coleman AL. Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure. Cochrane Database Syst Rev. 2017;2:CD012131.

74. Gangaputra S, Drye L, Vaidya V, et al. Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 2013;155(2):206-212.

75. Freeman WR, Van Natta ML, Jabs D, et al. Vision function in HIV-infected individuals without retinitis: report of the Studies of Ocular Complications of AIDS Research Group. Am J Ophthalmol. 2008;145(3):453-462.

76. Atkins EJ, Biousse V, Newman NJ. The natural history of optic neuritis. Rev Neurol Dis. 2006;3(2):45-56.

77. Yeh EA, Graves JS, Benson LA, et al. Pediatric Optic Neuritis. Neurology. 2016;87(9 Suppl 2):S53-S58.

78. Herce H. Childhood Optic Neuritis. Available at https://emedicine.medscape.com/article/1217290-overview. Last accessed October 1, 2023.

79. Bonhomme GR, Waldman AT, Balcer LJ, et al. Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis. Neurology. 2009;72(10):881-885.

80. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015;8:CD001430.

81. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-1082.

82. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67(2):258-262.

83. Brady KM, Brar AS, Lee AG, Coats DK, Paysse EA, Steinkuller PG. Optic neuritis in children: clinical features and visual outcome.J AAPOS. 1999;3(2):98-103.

84. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012;5:CD005556.

85. Lindsley K, Nichols JJ, Dickersin K. Interventions for acute internal hordeolum. Cochrane Database Syst Rev. 2017;1:CD007742.

86. U.S. Food and Drug Administration. FDA Approves New Medication for Dry Eye Disease. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-dry-eye-disease. Last accessed October 1, 2023.

87. Ervin A-M, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2017;6:CD006775.

88. American Academy of Ophthalmology. Choosing Wisely: Five Things Ophthalmologists and Patients Should Question. Available at https://www.aao.org/education/choosing-wisely. Last accessed October 1, 2023.

89. DeBacker C. Entropion or Ectropion Repair. Available at https://emedicine.medscape.com/article/1844045-overview. Last accessed October 1, 2023.

90. Kalyani PS, Fawzi AA, Gangaputra S, et al. Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with visual function. Am J Ophthalmol. 2012;153(3):428-433.

91. Fraunfelder FW. Ocular side effects from herbal medicines and nutritional supplements. Am J Ophthalmol. 2004;138(4):639-647.

92. Gilliland GD. Dermatochalasis. Available at https://emedicine.medscape.com/article/1212294-overview. Last accessed October 1, 2023.

93. Morris CL, Chesnutt DA. Acquired Ptosis: Evaluation and Management. Available at https://www.aao.org/eyenet/article/acquired-ptosis-evaluation-management. Last accessed October 1, 2023.

94. Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. Dermatol Online J. 2005;11(1):9.

95. Popovic Suic S, Cerovski B, Tojagic M. Lid retraction etiology. Acta Med Croatica. 2004;58(5):407-409.

96. Aldave AJ, Maus M, Rubin PA. Advances in the management of lower eyelid retraction. Facial Plast Surg. 1999;15(3):213-224.

97. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008;71:1275-1282.

98. Peckham EL, Lopez G, Shamim EA, et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol. 2011;18(3):382-386.

99. Vaziri K, Schwartz SG, Flynn HW Jr, Kishor KS, Moshfeghi AA. Eye-related emergency department visits in the United States, 2010. Ophthalmology. 2016;123(4):917-919.

100. Matsa E, Shi J, Wheeler KK, et al. Trends in U.S. emergency department visits for pediatric acute ocular injury. JAMA Ophthalmol. 2018;136(8):895–903.

101. Channa R, Zafar SN, Canner JK. Epidemiology of eye-related emergency department visits. JAMA Ophthalmol. 2016;134(3):312-319.

102. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30-39.

103. Chen AJ, Linakis JG, Mello MJ, Greenberg PB. Epidemiology of infant ocular and periocular injuries from consumer products in the United States, 2001–2008. J AAPOS. 2013;17(3):239-242.

104. American Association of Ophthalmologists. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy, 2016. Available at https://www.aao.org/education/clinical-statement/revised-recommendations-on-screening-chloroquine-h. Last accessed October 1, 2023.

105. Chen T, Kistamgari S, Smith GA. Consumer product-related pediatric eye injuries treated in United States emergency departments. Ophthalmic Epidemiol. 2023 Aug;30(4):424-433.

106. Chen AJ, Kim JG, Linakis JG, Mello MJ, Greenberg PB. Eye injuries in the elderly from consumer products in the United States: 2001–2007. Graefes Arch Clin Exp Ophthalmol. 2013;251(3):645-651.

107. American Association for Pediatric Ophthalmology and Strabismus. Eye Safety. Available at https://aapos.org/viewdocument/eye-safety. Last accessed October 1, 2023.

108. Chen AJ, Chan JJ, Linakis JG, Mello MJ, Greenberg PB. Age and consumer product-related eye injuries in the United States. R I Med J. 2014;97(1):44-48.

109. Moren Cross J, Griffin R, Owsley C, McGwin G. Pediatric eye injuries related to consumer products in the United States, 1997–2006. J AAPOS. 2008;12(6):626-628.

110. McGwin G Jr, Hall TA, Seale J, Xie A, Owsley C. Consumer product-related eye injury in the United States, 1998–2002. J Safety Res. 2006;37(5):501-506.

111. Seidman CJ, Linakis JG, Mello MJ, Greenberg PB. Aerosol container-related eye injuries in the United States: 1997–2009.Am J Ophthalmol. 2011;151(6):1041-1046.

112. American Academy of Ophthalmology. Eye Injuries from Paintball Guns, Air Guns and Other Projectile Toys. Available at https://www.aao.org/eye-health/news/combating-eye-injuries-from-air-guns. Last accessed October 1, 2023.

113. American Academy of Ophthalmology. ACR, AAD, RDS, and AAO 2020 Joint Statement on Hydroxychloroquine Use with Respect to Retinal Toxicity. Available at https://www.aao.org/education/clinical-statement/acr-aad-rds-aao-2020-joint-statement-on-hydroxychl-2. Last accessed October 1, 2023.

114. National Cancer Institute. Cancer in Children and Adolescents. Available at https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet. Last accessed October 1, 2023.

115. Smith B, Pledger D. 2022 Fireworks Annual Report. Bethesda, MD: U.S. Consumer Product Safety Commission; 2022.

116. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.

117. Ahmad SM, Esmaeli B. Metastatic tumors of the orbit and ocular adnexa. Curr Opin Ophthalmol. 2007;18(5):405-413.

118. American Academy of Ophthalmology. Recognizing and Treating Eye Injuries. Available at https://www.aao.org/eye-health/tips-prevention/injuries. Last accessed October 1, 2023.

119. American Academy of Ophthalmology, American Academy of Pediatricians. Joint Policy Statement: Protective Eyewear for Young Athletes. San Francisco, CA: American Academy of Ophthalmology; 2013.

120. Rodriguez JO, Lavina AM, Agarwal A. Prevention and treatment of common eye injuries in sports. Am Fam Physician. 2003;67(7): 1481-1488.

121. National Cancer Institute. Retinoblastoma Treatment (PDQ). Available at https://www.cancer.gov/types/retinoblastoma/hp/retinoblastoma-treatment-pdq. Last accessed October 1, 2023.

122. Kriz PK, Comstock RD, Zurakowski D, et al. Effectiveness of protective eyewear in reducing eye injuries among high school field hockey players. Pediatrics. 2012;130(6):1069-1075.

123. Lincoln AE, Caswell AV, Almquist JL, et al. Effectiveness of the women's lacrosse protective eyewear mandate in the reduction of eye injuries. Am J Sports Med. 2012;40(3):611-614.

124. Forrest KY, Cali JM. Epidemiology of lifetime work-related eye injuries in the U.S. population associated with one or more lost days of work. Ophthalmic Epidemiol. 2009;16(3):156-162.

125. Bureau of Labor Statistics. Nonfatal Occupational Injuries and Illnesses Requiring Days Away from Work, 2015. Available at https://www.bls.gov/news.release/pdf/osh2.pdf. Last accessed October 1, 2023.

126. Centers for Disease Control and Prevention. The National Institute for Occupational Safety and Health (NIOSH): Traumatic Occupational Injuries. Available at https://www.cdc.gov/niosh/injury/fastfacts.html. Last accessed October 1, 2023.

128. Wong JR, Tucker MA, Kleinerman RA, Devesa SS. Retinoblastoma incidence patterns in the U.S. Surveillance, Epidemiology, and End Results program. JAMA Ophthalmol. 2014;132(4):478-483.

129. Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics. 2003;112(6):1248-1255.

130. National Cancer Institute. Intraocular (Uveal) Melanoma Treatment (PDQ). Available at https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq. Last accessed October 1, 2023.

131. Occupational Safety and Health Administration. Eye and Face Protection eTool. Available at https://www.osha.gov/SLTC/etools/eyeandface. Last accessed October 1, 2023.

132. Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.

133. Kuo DZ, O'Connor KG, Flores G, Minkovitz CS. Pediatricians' use of language services for families with limited English proficiency. Pediatrics. 2007;119(4):920-927.

134. Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care. J Gen Intern Med. 2003;18(1):44-52.

135. Pokhrel P, Loftus SA. Ocular emergencies. Am Fam Physician. 2007;76(6):829-836.

136. MedlinePlus. Corneal Ulcers and Infections. Available at https://medlineplus.gov/ency/article/001032.htm. Last accessed October 1, 2023.

137. Wipperman JL, Dorsch JN. Evaluation and management of corneal abrasions. Am Fam Physician. 2013;87(2):114-120.

138. Wakai A, Lawrenson JG, Lawrenson AL, et al. Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions. Cochrane Database Syst Rev. 2017;5:CD009781.

139. Carley F, Carley S. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary: mydriatics in corneal abrasion. Emerg Med J. 2001;18(4):273.

140. Meek R, Sullivan A, Favilla M, Lamour I, Guastalegname S. Is homatropine 5% effective in reducing pain associated with corneal abrasion when compared with placebo? A randomized controlled trial. Emerg Med Australas. 2010;22(6):507-513.

141. Fraser S. Corneal abrasion. Clin Ophthalmol. 2010;4:387-390.

142. Thiel B, Sarau A, Ng D. Efficacy of topical analgesics in pain control for corneal abrasions: a systematic review. Cureus. 2017;9(3):e1121.

143. Lim CH, Turner A, Lim BX. Patching for corneal abrasion. Cochrane Database Syst Rev. 2016;7:CD004764.

144. Mukherjee P, Sivakumar A, Mackway-Jones K. Tetanus prophylaxis in superficial corneal abrasions. Emerg Med J. 2003;20(1):62-64.

145. Mimura T, Usui T, Yamagami S, et al. Recent causes of subconjunctival hemorrhage. Ophthalmologica. 2010;224(3):133-137.

146. DeRidder CA, Berkowitz CD, Hicks RA, Laskey AL. Subconjunctival hemorrhages in infants and children: a sign of nonaccidental trauma. Pediatr Emerg Care. 2013;29(2):222-226.

147. Gelston CD. Common eye emergencies. Am Fam Physician. 2013;88(8):515-519.

148. Ing EB. Eyelid Laceration Treatment and Management. Available at https://emedicine.medscape.com/article/1212531-treatment. Last accessed October 1, 2023.

149. Kosoko A, Vu Q, Kosoko-Lasaki O. Chemical ocular burns: a case review. Am J Clin Med. 2009;6(3):41-49.

150. Roper-Hall MJ. Thermal and chemical burns. Trans Ophthalmol Soc U K. 1965;85:631-653.

151. Mackway-Jones K, Marsden J. Ascorbate for alkali burns to the eye. Emerg Med J. 2003;20(5):465-466.

152. Acerra JR. Globe Rupture. Available at https://emedicine.medscape.com/article/798223-overview. Last accessed October 1, 2023.

153. Cain W Jr, Sinskey RM. Detection of anterior chamber leakage with Seidel's test. Arch Ophthalmol. 1981;99(11):2013.

154. Pandya HK. Retinal Detachment. Available at https://emedicine.medscape.com/article/798501-overview. Last accessed October 1, 2023.

155. National Institutes of Health. Visual Impairment, Blindness Cases in U.S. Expected to Double By 2050. Available at https://www.nih.gov/news-events/news-releases/visual-impairment-blindness-cases-us-expected-double-2050. Last accessed October 1, 2023.

156. Boyd K. Strabismus in Children. Available at https://www.aao.org/eye-health/diseases/strabismus-in-children. Last accessed October 1, 2023.

157. American Academy of Ophthalmologists. Pediatric Eye Evaluations PPP 2022. Available at https://www.aao.org/education/preferred-practice-pattern/pediatric-eye-evaluations-ppp-2022. Last accessed October 1, 2023.

158. Gulati S, Andrews CA, Apkarian AO, et al. Effect of gestational age and birth weight on the risk of strabismus among premature infants. JAMA Pediatr. 2014;168(9):850-856.

159. Jones-Jordan L, Wang X, Scherer RW, Mutti DO. Spectacle correction versus no spectacles for prevention of strabismus in hyperopic children. Cochrane Database Syst Rev. 2014;8:CD007738.

160. Boyd K. Amblyopia: What is Lazy Eye? Available at https://www.aao.org/eye-health/diseases/amblyopia-lazy-eye. Last accessed October 1, 2023.

161. Gunton KB. Advances in amblyopia: what have we learned from PEDIG trials? Pediatrics. 2013;131(3):540-547.

162. Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005;123(4):437-447.

163. American Academy of Ophthalmologists. Amblyopia PPP 2022. Available at https://www.aao.org/education/preferred-practice-pattern/amblyopia-ppp-2022. Last accessed October 1, 2023.

164. Taylor K, Elliott S. Interventions for strabismic amblyopia. Cochrane Database Syst Rev. 2014;7:CD006461.

165. Li T, Shotton K. Conventional occlusion versus pharmacologic penalization for amblyopia. Cochrane Database Syst Rev. 2009;4:CD006460.

166. Repka MX, Kraker RT, Holmes JM, et al. Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial. JAMA Ophthalmol. 2014;132(7):799-805.

167. Wallace MP, Stewart CE, Moseley MJ, et al. Compliance with occlusion therapy for childhood amblyopia. Invest Ophthalmol Vis Sci. 2013;54(9):6158-6166.

168. Zhang X, Cotch MF, Ryskulova A, et al. Vision health disparities in the United States by race/ethnicity, education, and economic status: findings from two nationally representative surveys. Am J Ophthalmol. 2012;154(6 Suppl):S53-S62.

169. Hong T, Mitchell P, Burlutsky G, Samarawickrama C, Wang JJ. Visual impairment and the incidence of falls and fractures among older people: longitudinal findings from the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. 2014;55(11):7589-7593.

170. Feinberg JL, Rogers PA, Sokol-McKay D. Age-related eye disease and medication safety. Ann Longterm Care. 2009;17:17-22.

171. Virgili G, Acosta R, Grover LL, Bentley SA, Giacomelli G. Reading aids for adults with low vision. Cochrane Database Syst Rev. 2013;10:CD003303.

172. American Academy of Ophthalmologists. Vision Rehabilitation PPP 2022. Available at https://www.aao.org/education/preferred-practice-pattern/vision-rehabilitation-ppp-2022. Last accessed October 1, 2023.

173. American Academy of Ophthalmologists. Primary Open-Angle Glaucoma PPP 2020. Available at https://www.aao.org/education/preferred-practice-pattern/vision-rehabilitation-ppp-2022. Last accessed October 1, 2023.

174. Riaz Y, de Silva SR, Evans JR. Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus phacoemulsification with posterior chamber intraocular lens for age-related cataract. Cochrane Database Syst Rev. 2013;10:CD008813.

175. Mangione CM, Barry MJ, Nicholson WK. Screening for primary open-angle glaucoma: U.S. Preventive Services Task Force recommendation statement. JAMA. 2022;327(20):1992-1997.

176. Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF5-ORSF13.

177. Lundeen EA, Burke-Conte Z, Rein DB, et al. Prevalence of diabetic retinopathy in the U.S. in 2021. JAMA Ophthalmol. 2023;141(8):747-754.

178. Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol. 2014;158(6):1121-1129.

179. Zhao D, Cho J, Kim MH, Friedman DS, Guallar E. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2014;158(6):1121-1129.

180. Tehrani S. Gender difference in the pathophysiology and treatment of glaucoma. Curr Eye Res. 2014;6:1-10.

181. Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and primary open-angle glaucoma: a meta-analysis. Am J Ophthalmol. 2014;158(3):615-627.

182. Fernandez Lopez E, Karaca EE, Ekici F, Waisbourd M, Spaeth GL. Symptoms reported by patients with varying stages of glaucoma: review of 401 cases. Can J Ophthalmol. 2014;49(5):420-425.

183. Schwartz GG. Eye cancer incidence in U.S. States and access to fluoridated water. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1707-1711.

184. Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158(4):271-279.

185. American Glaucoma Society. Position Statement on Marijuana and the Treatment of Glaucoma. Available at https://www.americanglaucomasociety.net/about/statements. Last accessed October 1, 2023.

186. Chou R, Selph S, Blazina I, et al. Screening for Glaucoma in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;327(20):1998–2012.

187. National Glaucoma Research. Is There a Connection Between Diet, Eye Pressure and Glaucoma? Available at https://www.brightfocus.org/glaucoma/article/there-connection-between-diet-and-glaucoma. Last accessed October 1, 2023.

188. American Academy of Ophthalmologists. Age-Related Macular Degeneration PPP 2019. Available at https://www.aao.org/education/preferred-practice-pattern/age-related-macular-degeneration-ppp. Last accessed October 1, 2023.

189. Patel M, Smyth E, Chapman PB, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011;17(8):2087-2100.

190. Fisher DE, Klein BE, Wong TY, et al. Incidence of age-related macular degeneration in a multi-ethnic United States population: the multi-ethnic study of atherosclerosis. Ophthalmology. 2016;123(6):1297-1308.

191. Luke JJ, Triozzi PL, McKenna KC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015;28(2):135-147.

192. Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology. 2014;121(6):1281-1288.

193. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.

194. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration—emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-471.

195. Wang X, Jiang C, Zhang Y, et al. Role of lutein supplementation in the management of age-related macular degeneration: meta-analysis of randomized controlled trials. Ophthalmic Res. 2014;52(4):198-205.

196. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139.

197. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.

198. Retina Today. Another Anti-VEGF Agent for Treatment of Neovascular AMD. Available at https://retinatoday.com/articles/2015-july-aug/another-anti-vegf-agent-for-treatment-of-neovascular-amd. Last accessed October 1, 2023.

199. Ophthalmology Times. Novel Anti-VEGF Agent Approved in China May Reduce Injection Frequency. Available at https://www.ophthalmologytimes.com/view/novel-anti-vegf-agent-approved-china-may-reduce-injection-frequency. Last accessed October 1, 20230.

200. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma.Curr Opin Ophthalmol. 2014;25(3):234-239.

201. Glover K, Mishra D, Singh TRR. Epidemiology of ocular manifestations in autoimmune disease.Front Immunol. 2021;12:744396.

202. Fong DS, Aiello LP, Gardner TW, et al. Diabetic retinopathy.Diabetes Care. 2003;26(suppl 1):S99-S102.

203. ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes.N Engl J Med. 2010;363(3):233-244.

204. 204. Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes Eye Study.Ophthalmology. 2014;121(12):2443-2451.

205. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review.JAMA. 2007;298(8):902-916.

206. American Optometric Association. Clinical Practice Guidelines: Evidence-Based Clinical Practice Guideline Eye Care of the Patient with Diabetes Mellitus. Available at https://aoa.uberflip.com/i/374890-evidence-based-clinical-practice-guideline-diabetes-mellitus. Last accessed October 1, 2023.

207. Fraser-Bell S, Symes R, Vaze A. Hypertensive eye disease: a review.Clin Exp Ophthalmol. 2017;45:45-53.

208. Baker CW, Glassman AR, Beaulieu WT, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880-1894.

209. Leasher JL, Bourne RRA, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010.Diabetes Care. 2016;39:1643-1649.

210. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema.Clin Ophthalmol. 2013;7:1257-1267.

211. International Diabetes Federation. Diabetes Facts and Figures. Available at https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Last accessed October 1, 2023.

212. Jampol LM, Glassman AR, Sun J. Evaluation and care of patients with diabetic retinopathy.N Engl J Med. 2020;382:1629-1637.

213. American Academy of Ophthalmologists. Diabetic Retinopathy PPP 2019. Available at https://www.aao.org/education/preferred-practice-pattern/diabetic-retinopathy-ppp. Last accessed October 1, 2023.

214. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Cochrane Database Syst Rev. 2017;6:CD007419.

215. Lexicomp Online. Available at https://online.lexi.com. Last accessed October 1, 2023.

216. 216. Mavrikakis E. Macular Edema in Diabetes. Available at https://emedicine.medscape.com/article/1224138-overview. Last accessed October 1, 2023.

217. Zwarenstein M, Shiller SK, Croxford R. Printed educational messages aimed at family practitioners fail to increase retinal screening among their patients with diabetes: a pragmatic cluster randomized controlled trial [ISRCTN72772651].Implement Sci. 2014;9:87.

218. Wong TY, Mitchell P. Hypertensive retinopathy.N Engl J Med. 2004;351(22):2310-2317.

219. Wong TY, Klein R, Sharrett AR, et al. The prevalence and risk factors of retinal microvascular abnormalities in older people: the Cardiovascular Health Study.Ophthalmology. 2003;110(4):658-666.

220. Davis JL. Intraocular lymphoma: a clinical perspective.Eye (Lond). 2013;27(2):153-162.

221. Sobolewska B, Chee SP, Zaguia F, et al. Vitreoretinal lymphoma.Cancers (Basel). 2021;13(16):3921.

222. Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era.Retina. 2005;25(5):633-649.

223. Shi Y, Jia R, Fan X. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.Onco Targets Ther. 2017;10:2483-2489.

224. BaşZ, Sharpe J, Yaghy A, et al. Prevalence of and associated factors for eyelid cancer in the American Academy of Ophthalmology Intelligent Research in Sight Registry.Ophthalmol Sci. 2022;3(1):100227.

225. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer Version 2.2024. Available at https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Last accessed October 1, 2023.

226. Lai TY, Wong RL, Luk FO, et al. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era.Clin Experiment Ophthalmol. 2011;39(2):99-104.

227. Prabhakaran VC, Gupta A, Huilgol SC, Selva D. Basal cell carcinoma of the eyelids.Compr Ophthalmol Update. 2007;8(1):1-14.

228. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/introduction. Last accessed October 1, 2023.

Evidence-Based Practice Recommendations Citations

1. American Optometric Association.Comprehensive Adult Eye and Vision Examination. St. Louis, MO: American Optometric Association; 2015. Available at https://www.aoa.org/AOA/Documents/Practice%20Management/Clinical%20Guidelines/EBO%20Guidelines/Comprehensive%20Adult%20Eye%20and%20Vision%20Exam.pdf. Last accessed November 29, 2023.

2. Wippold FJ II, Cornelius RS, Berger KL, et al.ACR Appropriateness Criteria: Orbits, Vision, and Visual Loss. Reston, VA: American College of Radiology; 2017. Available at https://acsearch.acr.org/docs/69486/Narrative. Last accessed November 29, 2023.

3. Cruz OA, Repka MX, Hercinovic A, et al. Amblyo6420pia preferred practice pattern.Ophthalmology. 2023;130:136-178. Available at https://www.aaojournal.org/article/S0161-6420(22)00865-X/fulltext. Last accessed November 29, 2023.

4. American Optometric Association.Evidence-Based Clinical Practice Guideline: Eye Care of the Patient with Diabetes Mellitus. 2nd ed. St. Louis, MO: American Optometric Association; 2019. Available at https://aoa.uberflip.com/i/1183026-evidence-based-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus-second-edition/1?m4=. Last accessed November 29, 2023.


Copyright © 2023 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.